Effects of Face Mask Continuous Positive Airway Pressure Vs. Noninvasive Ventilation Vs. High-flow Nasal Oxygen on Intubation-free Survival in Acute Hypoxemic Respiratory Failure: the TRIPOD Randomized Clinical Trial

Обзор

Acute hypoxemic respiratory failure (AHRF) is a common indication for admission to an intensive care unit (ICU), with mortality exceeding 50% in cases where invasive mechanical ventilation is needed. Therefore, assessment of the most adequate oxygen strategy to avoid intubation in patients with AHRF deserves consideration.Previous studies have indicated that non-invasive oxygenation strategies, including high-flow nasal oxygen (HFNO), helmet or face mask noninvasive ventilation (NIV), and continuous positive airway pressure (CPAP), are effective in preventing endotracheal intubation in adult patients with AHRF when compared to the standard oxygen therapy. However, the optimal non-invasive oxygenation strategies remain uncertain. This study aim to determine whether CPAP, compared with HFNC or NIV, increase the intubation-free survival during study period in patients with AHRF.

Вмешательства

• Устройство Continuous Positive Airway Pressure
  1. Patients were placed at a 45-degree supine position, and noninvasive ventilation was delivered to the patient through a face mask connected to an ICU ventilator. 2. PEEP was started at 5 cm H2O with a FiO2 of 0.5 at initiation. PEEP and FiO2 were titrated to maintain SpO2 between 94 and 98%, remaining constant for at least 5 min. 3. CPAP was initiated with a first session of at least 4 h, the minimally required duration of noninvasive ventilation was 16 hours per day for at least 2 calendar d
• Устройство High-flow nasal oxygen
  1. Oxygen was passed through a heated humidifier (MR850, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs, with a gas flow rate of 50 liters per minute and an FiO2 of 0.5 at initiation. HFNO heating temperature was prespecified at 37°C. 2. FiO2 will be titrated to maintain SpO2 between 94 and 98%, remaining constant for at least 5 min. 3. HFNO was applied for at least 2 calendar days.
• Устройство Non-invasive ventilation
  1. Patients were placed at a 45-degree supine position, and noninvasive ventilation was also delivered to the patient through a face mask connected to an ICU ventilator. The mask most appropriate for the patient will be selected and adjusted to minimize leakage and pressure points. 2. The inspiratory positive airway pressure (pressure support plus PEEP) was initiated between 12 and 14 cm H2O, PEEP was started at 5 cm H2O with a FiO2 of 0.5 at initiation. FiO2 was titrated to maintain SpO2 betwee

Первичные конечные точки

• Intubation-free survival rate [Срок оценки: From randomization to 28 days]

Вторичные конечные точки (12)

• 28-day mortality [Срок оценки: From randomization to 28 days]
• Intubation rate within 28 days [Срок оценки: From randomization to 28 days]
• A ranked composite score incorporating death and intubation through day 28 [Срок оценки: From randomization to 28 days]
• Meeting the prespecified criteria for intubation within 28 days. [Срок оценки: From randomization to 28 days]
• ICU mortality [Срок оценки: From randomization to ICU discharge, assessed up to 60 days]
• In-hospital mortality [Срок оценки: From randomization to hospital discharge, assessed up to 60 days]
• Change in Discomfort scale after 1 hour of randomization [Срок оценки: Time from randomization to 1hour]
• Invasive ventilator-free days at 28 days [Срок оценки: From randomization to 28 days]
• Circulatory support-free days at day 28 [Срок оценки: From randomization to 28 days]
• Time from randomization to an improvement of two points on a seven-category ordinal scale [Срок оценки: From randomization to 28 days]
• ICU-free days at day 28 [Срок оценки: From randomization to 28 days]
• Hospital-free days at day 28 [Срок оценки: From randomization to 28 days]

Критерии участия

Критерии включения

• Age≥18 yrs;
• A ratio of the partial pressure of arterial oxygen (PaO2) to the FiO2 of 300 mm Hg or less, or a ratio of pulse oximetry oxygen saturation (SpO2) to the FiO2 of 315 or less (SpO2≤97%) and the need for (1) noninvasive positive pressure ventilation with at least 5 cm H2O PEEP, or (2) high-flow nasal cannula at 30L/min or higher, or (3) standard oxygen with oxygen flow rate of at least 10 L/min;
• Sign informed consent.

Критерии исключения

• Patients that have already received Continuous positive airway pressure, Noninvasive ventilation continuously for more than 24 hours before the screening visit.
• Previous bout of mechanical ventilation during index hospitalization.
• Exacerbation of chronic lung disease, including asthma or chronic obstructive pulmonary disease.
• Moderate to severe cardiac insufficiency (New York Heart Association class >II or left ventricular ejection fraction<50%) or cardiogenic pulmonary edema.
• Hemodynamic dysfunction, defined as vasopressor dose > 0.3 µg/kg/min of norepinephrine-equivalent to maintain systolic blood pressure > 90 mm Hg.
• Impaired consciousness with a Glasgow coma score ≤ 12.
• Patients with urgent need for intubation, including respiratory or cardiac arrest, respiratory pauses with loss of consciousness or gasping for air, severe hypoxemia defined as SpO2 lower than 90% despite maximal oxygen support.
• Patients with contraindication to NIV according to the French consensus conference, patient refusal, cardiorespiratory arrest, coma, non-drained pneumothorax, unresolved vomiting, upper airway obstruction, hematemesis or severe facial trauma, thoracic or abdominal surgery in the previous 7 days.
• A do-not-intubate order at time of inclusion.
• Pregnancy.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Китай · 1 центр

• Zhongda Hospital, School of Medicine, Southeast University — Нанкин

Идентификаторы

NCT: NCT06795971 · TRIPOD Study

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗